Logiscreen

Arrowhead Pharmaceuticals Inc

$73.09
Market Cap 10.23B
ROE -55.4%
Gross Margin 100.0%
Debt/Equity 2.2
Current Ratio 6.2
Revenue QoQ -86.4%
EPS QoQ -1.3%
F-Score 3

About

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-34.98
vs median 33.61
P/B
17.14
vs median 2.16
ROE
-0.55
vs median 0.09

Lower quality - review fundamentals carefully

Large-cap company with established market presence

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics